Rhenman & Partners Asset Management AB Sells 25,200 Shares of Inspire Medical Systems, Inc. $INSP

Rhenman & Partners Asset Management AB lowered its stake in Inspire Medical Systems, Inc. (NYSE:INSP) by 41.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,800 shares of the company’s stock after selling 25,200 shares during the quarter. Rhenman & Partners Asset Management AB’s holdings in Inspire Medical Systems were worth $3,302,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of INSP. CWM LLC increased its stake in shares of Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after acquiring an additional 242 shares in the last quarter. Havemeyer Place LP bought a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $39,000. V Square Quantitative Management LLC bought a new stake in shares of Inspire Medical Systems in the 4th quarter valued at $40,000. Larson Financial Group LLC increased its stake in shares of Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock valued at $48,000 after acquiring an additional 638 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in shares of Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares in the last quarter. Institutional investors own 94.91% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on INSP shares. Morgan Stanley set a $60.00 price objective on shares of Inspire Medical Systems in a research note on Wednesday, February 18th. Robert W. Baird lowered their price objective on shares of Inspire Medical Systems from $63.00 to $50.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. JPMorgan Chase & Co. lowered their price objective on shares of Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating for the company in a research note on Tuesday, May 5th. Oppenheimer reiterated a “market perform” rating on shares of Inspire Medical Systems in a research note on Thursday, May 7th. Finally, Wells Fargo & Company lowered their price objective on shares of Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 5th. Four investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $81.84.

Inspire Medical Systems Trading Up 0.7%

Shares of INSP stock opened at $42.74 on Friday. The firm has a market capitalization of $1.23 billion, a PE ratio of 9.52, a price-to-earnings-growth ratio of 4.38 and a beta of 0.73. The firm has a fifty day simple moving average of $48.05 and a two-hundred day simple moving average of $71.79. Inspire Medical Systems, Inc. has a 12 month low of $38.91 and a 12 month high of $147.03.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The business had revenue of $204.58 million during the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. Inspire Medical Systems’s quarterly revenue was up 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. On average, equities analysts predict that Inspire Medical Systems, Inc. will post 0.91 earnings per share for the current fiscal year.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.